Specific Therapeutic Areas

Part 3 - Specific Therapeutic Areas

Published online by Cambridge University Press: 29 May 2020

Edited by

Peter M. Haddad and

David J. Nutt

Show author details

Peter M. Haddad: Affiliation:
Hamad Medical Corporation, Qatar
David J. Nutt: Affiliation:
Centre for Neuropsychopharmacology, Division of Psychiatry, Department of Brain Sciences, Imperial College London

Book contents

Get access

Type: Chapter
Information: Seminars in Clinical Psychopharmacology , pp. 525 - 652

DOI: https://doi.org/10.1017/9781911623465 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allen, AJ, Kurlan, RM, Gilbert, DL, et al. (2005). Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology, 65, 1941–1949.Google Scholar

Baldwin, DS, Kosky, N (2007). Off-label prescribing in psychiatric practice. Adv Psychiatr Treat, 13, 414–422.Google Scholar

Bratt, AM, Masanyero-Bennie, B, Kelley, SP (2017). A meta-analysis of the efficacy of immediate release methylphenidate to reduce hyperactivity in children with autistic spectrum disorder. J Pharm Sci Exp Pharmacol, 2017, 11–20.Google Scholar

Brent, D, Emslie, G, Clarke, G (2008). Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA, 299, 901–913.Google Scholar

Cipriani, A, Zhou, X, Del Giovane, C, et al. (2016). Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet, 388, 881–890.CrossRef Google Scholar PubMed

Coghill, D, Seth, S (2015). Effective management of attention-deficit/hyperactivity disorder (ADHD) through structured re-assessment: the Dundee ADHD Clinical Care Pathway. Child Adolesc Psychiatry Ment Health, 9, 52. doi:10.1186/s13034-015-0083-2.Google Scholar

Cohen, SC, Mulqueen, JM, Ferracioli-Oda, E, et al. (2015). Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry, 54, 728–736.Google Scholar

Cortese, S, Holtmann, M, Banaschewski, T, et al. (2013). Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry, 54, 227–246.Google Scholar

Eddy, CM, Cavanna, AE, Gulisano, M, et al. (2011). Clinical correlates of quality of life in Tourette syndrome. Mov Disord, 26, 735–738.CrossRef Google Scholar PubMed

Emslie, GJ, Mayes, T, Porta, G, et al. (2010). Treatment of resistant depression in adolescents (TORDIA): week 24 outcomes. Am J Psychiatry, 167, 782–791.Google Scholar

European Medicines Agency (2007). Regulation (EC) No 1901/2006 of the European Parliament and of the Council on medicinal products for paediatric use, as amended by Regulation (EC) No 1902/2006 (online). Available at: www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000068.jsp (last accessed 12.6.18).Google Scholar

Fraguas, D, Correll, CU, Merchan-Naranjo, J, et al. (2011). Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol, 21, 621–645.Google Scholar

Gibbons, RD, Brown, CH, Hur, K, et al. (2007). Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry, 164, 1356–1363.Google Scholar

Goodyer, I, Dubicka, B, Wilkinson, P, et al. (2007). Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ, 335, 142.Google Scholar

Gusmao, R, Quintao, S, McDaid, D, et al. (2013). Antidepressant utilization and suicide in Europe: an ecological multi-national study. PLoS One, 8, e66455.Google Scholar

Hammad, TA, Laughren, T, Racoosin, J (2006). Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry, 63(3), 332–339.Google Scholar

Hazell, P, Mirzaie, M (2013). Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev, (6), CD002317.Google Scholar

Hetrick, SE, McKenzie, JE, Cox, GR, Simmons, MB, Merry, SN (2012). Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev, (11), CD004851.Google Scholar

Hollander, E, Phillips, A, Chaplin, W, et al. (2005). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology, 30, 582–589.Google Scholar PubMed

Hollander, E, Chaplin, W, Soorya, L, et al. (2010). Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology, 35, 990–998.Google Scholar

Joint Formulary Committee (2019). British National Formulary for Children (online). London: BMJ Group and Pharmaceutical Press.Google Scholar

Kendall, T, Hollis, C, Stafford, M, Taylor, C; Guideline Development Group (2013). Recognition and management of psychosis and schizophrenia in children and young people: summary of NICE guidance. BMJ, 346, f150.Google Scholar

Le Noury, J, Nardo, JM, Healy, D, et al. (2015). Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ, 351, h4320.Google Scholar

Leslie, LK, Newman, TB, Chesney, PJ, et al. (2005). The Food and Drug Administration’s deliberations on antidepressant use in pediatric patients. Pediatrics, 116, 195–204.Google Scholar

Malone, RP, Gratz, SS, Delaney, MA, Hyman, SB (2005). Advances in drug treatments for children and adolescents with autism and other pervasive developmental disorders. CNS Drugs, 19, 923–934.Google Scholar

March, J, Silva, S, Petrycki, S, et al.; Treatment for Adolescents with Depression Study (TADS) Team (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA, 292, 807–820.Google Scholar PubMed

Marcus, RN, Owen, R, Kamen, L, et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry, 48, 1110–1119.CrossRef Google Scholar PubMed

McClellan, L, Dominick, KC, Pedapati, EV, Wink, LK, Erickson, CA (2017). Lurasidone for the treatment of irritability and anger in autism spectrum disorders. Expert Opin Investig Drugs, 26, 985–989.Google Scholar

McDougle, CJ, Scahill, L, Aman, MG, et al. (2005). Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry, 162, 1142–1148.CrossRef Google Scholar

Medicines for Children (2015). Unlicensed Medicines (online). Available at: www.medicinesforchildren.org.uk/unlicensed-medicines (last accessed 12.6.18).Google Scholar

Murray, ML, Thompson, M, Santosh, PJ, Wong, IC (2005). Effects of the Committee on Safety of Medicines advice on antidepressant prescribing to children and adolescents in the UK. Drug Saf, 28(12), 1151–1157.Google Scholar

National Collaborating Centre for Mental Health (2015). Depression in children and young people: identification and management in primary, community and secondary care. Clinical guideline [CG28]. London: National Institute for Health and Clinical Excellence.Google Scholar

Owen, R, Sikich, L, Marcus, RN, et al. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124, 1533–1540.Google Scholar

Politte, LC, Scahill, L, Figueroa, J, et al. (2018). A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. Neuropsychopharmacology, 43, 1772–1778.Google Scholar

Rani, F, Murray, ML, Byrne, PJ, Wong, IC (2008). Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics, 121, 1002–1009.Google Scholar

Remington, G, Sloman, L, Konstantareas, M, Parker, K, Gow, R (2001). Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol, 21, 440–444.CrossRef Google Scholar PubMed

Roessner, V, Plessen, KJ, Rothenberger, A, et al.; ESSTS Guidelines Group (2011). European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry, 20, 173–196.CrossRef Google Scholar PubMed

Rosen, MS (2017). Lithium in child and adolescent bipolar disorder. Am J Psychiatry Resid J, 12, 3–5.CrossRef Google Scholar

Royal College of Paediatrics and Child Health (2013). The use of unlicensed medicines or licensed medicines for unlicensed applications in paediatric practice. London: Royal College of Paediatrics and Child Health.Google Scholar

Royal College of Psychiatrists (2007). Use of Licensed Medicines for Unlicensed Applications in Psychiatric Practice, 2nd ed. College Report CR210. London: Royal College of Psychiatrists.Google Scholar

Ryan, ND (1990). Heterocyclic antidepressants in children and adolescents. J Child Adolesc Psychopharmacol, 1, 21–31.Google Scholar

Rylance, GW, Moreland, TA (1980). Drug level monitoring in paediatric practice. Arch Dis Child, 55, 89–98.CrossRef Google Scholar PubMed

Sandor, P (1995). Clinical management of Tourette’s syndrome and associated disorders. Can J Psychiatry, 40, 577–583.Google Scholar

Scahill, L, Erenberg, G, Berlin, CM Jr, et al.; Tourette Syndrome Association Medical Advisory Board: Practice Committee (2006). Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx, 3, 192–206.Google Scholar

Sharma, AN, Arango, C, Coghill, D, et al. (2016). BAP Position Statement: Off-label prescribing of psychotropic medication to children and adolescents. J Psychopharmacol, 30, 416–421.Google Scholar

Shrestha, SS, Nelson, EE, Liow, JS, et al. (2014). Fluoxetine administered to juvenile monkeys: effects on the serotonin transporter and behavior. Am J Psychiatry, 171, 323–331.CrossRef Google Scholar PubMed

Simonoff, E, Pickles, A, Charman, T, et al. (2008). Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry, 47, 921–929.Google Scholar

Sonuga-Barke, EJ, Swanson, JM, Coghill, D, Decory, HH, Hatch, SJ (2004). Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry, 4, 28.Google Scholar

Sparks, JA, Duncan, BL (2013). Outside the black box: re-assessing pediatric antidepressant prescription. J Can Acad Child Adolesc Psychiatry, 22, 240–246.Google Scholar

Stone, M, Laughren, T, Jones, ML, et al. (2009). Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ, 339, b2880.Google Scholar

UK Government (1983). UK Medical Act 1983 (c54).Google Scholar

Usala, T, Clavenna, A, Zuddas, A, Bonati, M (2008). Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis. Eur Neuropsychopharmacol, 18, 62–73.Google Scholar

Verdellen, C, van de Griendt, J, Hartmann, A, Murphy, T; ESSTS Guidelines Group (2011). European clinical guidelines for Tourette syndrome and other tic disorders. Part III: behavioural and psychosocial interventions. Eur Child Adolesc Psychiatry, 20, 197–207.Google Scholar

Zheng, W, Li, XB, Xiang, YQ, et al. (2016). Aripiprazole for Tourette’s syndrome: a systematic review and meta-analysis. Hum Psychopharmacol, 31, 11–18.CrossRef Google Scholar PubMed

References

Adams, KH, Pinborg, LH, Svarer, C, et al. (2004). A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables. Neuroimage, 21, 1105–1113.Google Scholar

Alaka, KJ, Noble, W, Montejo, A, et al. (2014). Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry, 29, 978–986.Google Scholar

Baldwin, DS, Anderson, IM, Nutt, DJ, et al. (2014). Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol, 28, 403–439.Google Scholar

Barak, Y, Wittenberg, N, Naor, S, Kutzuk, D, Weizman, A (1999). Clozapine in elderly psychiatric patients: tolerability, safety, and efficacy. Compr Psychiatry, 40, 320–325.Google Scholar

Berry, SD, Lee, Y, Cai, S, Dore, DD (2013). Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Intern Med, 173, 754–761.Google Scholar

Bertz, RJ, Kroboth, PD, Kroboth, FJ, et al. (1997). Alprazolam in young and elderly men: sensitivity and tolerance to psychomotor, sedative and memory effects. J Pharmacol Exp Ther, 281, 1317–1329.Google Scholar

Bigos, KL, Bies, RR, Pollock, BG (2013). Pharmacokinetics and pharmacodynamics in late life. In Lavretsky, H, Sajatovic, M, Reynolds, C, eds., Late-Life Mood Disorders. New York: Oxford University Press, pp. 655–674.Google Scholar

Bishara, D, Taylor, D (2014). Adverse effects of clozapine in older patients: epidemiology, prevention and management. Drugs Aging, 31, 11–20.Google Scholar

Blier, P, Ward, HE, Tremblay, P, et al. (2010). Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry, 167, 281–288.Google Scholar

Boustani, M, Campbell, N, Munger, S, Maidment, I, Fox, C (2008). Impact of anticholinergics on the aging brain: a review and practical application. Aging Health, 4, 311–320.Google Scholar

Bowden, CL, Brugger, AM, Swann, AC, et al. (1994). Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA, 271(12), 918–924.Google Scholar

Bowie, MW, Slattum, PW (2007). Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother, 5, 263–303.Google Scholar

Calati, R, Salvina Signorelli, M, Balestri, M, et al. (2013). Antidepressants in elderly: metaregression of double-blind, randomized clinical trials. J Affect Disord, 147, 1–8.CrossRef Google Scholar PubMed

Carew, AM, Comiskey, C (2017). Treatment for opioid use and outcomes in older adults: a systematic literature review. Drug Alcohol Depend, 182, 48–57.Google Scholar

Carone, M, Asgharian, M, Jewell, NP (2014). Estimating the lifetime risk of dementia in the Canadian elderly population using cross-sectional cohort survival data. J Am Stat Assoc, 109, 24–35.Google Scholar

Chen, P, Dols, A, Rej, S, Sajatovic, M (2017). Update on the epidemiology, diagnosis, and treatment of mania in older-age bipolar disorder. Curr Psychiatry Rep, 19, 46. https://doi.org/10.1007/s11920-017–0804-8.Google Scholar

Chew, ML, Mulsant, BH, Pollock, BG, et al. (2008). Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc, 56, 1333–1341.Google Scholar

Chokhavatia, S, John, ES, Bridgeman, MB, Dixit, D (2016). Constipation in elderly patients with noncancer pain: focus on opioid-induced constipation. Drugs Aging, 33, 557–574.Google Scholar

Chung, JK, Nakajima, S, Shinagawa, S, et al.; Alzheimer’s Disease Neuroimaging Initiative (2016). Benzodiazepine use attenuates cortical β-amyloid and is not associated with progressive cognitive decline in nondemented elderly adults: a pilot study using F18-florbetapir positron emission tomography. Am J Geriatr Psychiatry, 24, 1028–1039.Google Scholar

Close, H, Reilly, J, Mason, JM, et al. (2014). Renal failure in lithium-treated bipolar disorder: a retrospective cohort study. PLoS One, 9(3), e90169. doi:10.1371/journal.pone.0090169. eCollection 2014.Google Scholar

Coupland, C, Dhiman, P, Morriss, R, et al. (2011). Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ, 343, d4551.Google Scholar

Crowe, SF, Stranks, EK (2018). The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis. Arch Clin Neuropsychol, 33, 901–911. doi:10.1093/arclin/acx120.Google Scholar

Cumming, RG, Le Couteur, DG (2003). Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs, 17, 825–837.Google Scholar

Davies, SJC, Eayrs, S, Pratt, P, Lennard, MS (2004). Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol, 57, 464–472.Google Scholar

Davies, SJ, Burhan, AM, Kim, D, et al. (2018a). Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia. J Psychopharmacol, 32(5), 509–523.Google Scholar

Davies, SJC, Jacob, B, Rudoler, D, et al. (2018b). Benzodiazepine prescription in Ontario residents aged 65 and over: a population-based study from 1998 to 2013. Ther Adv Psychopharmacol, 8, 99–114.Google Scholar

Department of Health Statistics and Informatics of the World Health Organization (2015). Disease burden and mortality estimates. Global Health Estimates 2015: DALYs by age, sex and cause. Available at: www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html (last accessed 14.8.18).Google Scholar

Depp, CA, Jeste, DV (2004). Bipolar disorder in older adults: a critical review. Bipolar Disord, 6, 343–367.Google Scholar

Dold, M, Aigner, M, Lanzenberger, R, Kasper, S (2015). Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol, 18(9), pyv047.Google Scholar

Doukas, N (2011). Older adults in methadone maintenance treatment: a literature review. J Soc Work Pract Addict, 11, 230–244.CrossRef Google Scholar

Esiri, MM, Morris, JH (1997). Practical approach to pathological diagnosis. In Esiri, MM, Morris, JH, eds., The Neuropathology of Dementia. Cambridge: Cambridge University Press, pp. 36–69.Google Scholar

Essali, A, Ali, G (2012). Antipsychotic drug treatment for elderly people with late-onset schizophrenia. Cochrane Database Syst Rev, (2), CD004162.Google Scholar

Evans, DL, Charney, DS, Lewis, L, et al. (2005). Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry, 58, 175–189.CrossRef Google Scholar PubMed

Finkelstein, J, Friedman, C, Hripcsak, G, Cabrera, M (2016). Pharmacogenetic polymorphism as an independent risk factor for frequent hospitalizations in older adults with polypharmacy: a pilot study. Pharmgenomics Pers Med, 14, 107–116.Google Scholar

Firoz, S, Carlson, G (2004). Characteristics and treatment outcome of older methadone-maintenance patients. Am J Geriatr Psychiatry, 12, 539–541.Google Scholar

Flockhart, D (undated). Flockhart Table P450 Drug Interaction Table. Available at: http://medicine.iupui.edu/clinpharm/ddis/main-table (last accessed 25.3.17).Google Scholar

Glassman, AH, O’Connor, CM, Califf, RM, et al. (2002). Sertraline treatment of major depression in patients with acute MI or unstable angina. Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. JAMA, 288, 701–709.Google Scholar

Goodwin, GM, Haddad, PM, Ferrier, IN, et al. (2016). Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 30, 495–553.Google Scholar

Gray, SL, Dublin, S, Yu, O, et al. (2016). Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ, 352, i90.Google Scholar

Gray, SL, Hart, LA, Perera, S, et al. (2018). Meta-analysis of interventions to reduce adverse drug reactions in older adults. J Am Geriatr Soc, 66, 282–288.Google Scholar

Greenblatt, DJ, Harmatz, JS, Shapiro, L, et al. (1991). Sensitivity to triazolam in the elderly. N Engl J Med, 324, 1691–1698.Google Scholar

Gum, AM, King-Kallimanis, B, Kohn, R (2009). Prevalence of mood, anxiety, and substance-abuse disorders for older Americans in the National Comorbidity Survey-Replication. Am J Geriatr Psychiatry, 17, 769–781.Google Scholar

Heun, R, Ahokas, A, Boyer, P, et al. (2013). The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J Clin Psychiatry, 74, 587–594.Google Scholar

Hewett, K, Gee, MD, Krishen, A, et al. (2010). Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol, 24, 1209–1216.Google Scholar

Jeste, DV, Barak, Y, Madhusoodanan, S, Grossman, F, Gharabawi, G (2003). International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry, 11, 638–647.Google Scholar

Joint Formulary Committee (2017). British National Formulary, No. 73. London: BMJ Group and Pharmaceutical Press, p. 296 and p. 304.Google Scholar

Katila, H, Mezhebovsky, I, Mulroy, A, et al. (2013). Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry, 21, 769–784.Google Scholar

Katona, C, Bercoff, E, Chiu, E, et al. (1999). Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial. J Affect Disord, 55, 203–213.Google Scholar

Katona, C, Hansen, T, Olsen, CK (2012). A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of LU AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol, 27, 215–223.Google Scholar

Katz, IR, Reynolds, CF, III Alexopoulos, GS, Hackett, D (2002). Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc, 50, 18–25.Google Scholar

Kerr, KP, Mate, KE, Magin, PJ, et al. (2014). The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians. J Clin Pharm Ther, 39, 383–389.Google Scholar

Kessler, D, MacNeill, SJ, Tallon, D, et al. (2018). Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised controlled trial (MIR). BMJ, 363, k4218.Google Scholar

Kinsella, K, He, W (2009). An Aging World. Washington, DC: National Institute on Aging and US Census Bureau.Google Scholar

Kirchheiner, J, Seeringer, A (2007). Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta, 1770, 489–494.Google Scholar

Klotz, U (2009). Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev, 41, 67–76.Google Scholar

Kok, RM, Vink, D, Heeren, TJ, Nolen, WA (2007). Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: an open, randomized, controlled trial. J Clin Psychiatry, 68, 1177–1185.Google Scholar

Kok, RM, Heeren, TJ, Nolen, WA (2011). Continuing treatment of depression in the elderly: a systematic review and meta-analysis of double-blinded randomized controlled trials with antidepressants. Am J Geriatr Psychiatry, 19, 249–255.Google Scholar

Kok, RM, Nolen, WA, Heeren, TJ (2012). Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants J Affect Disord, 141, 103–115.Google Scholar

Lampon, N, Tutor, JC (2012). Apparent clearance of valproic acid in elderly epileptic patients: estimation of the confounding effect of albumin concentration. Ups J Med Sci, 117, 41–46.Google Scholar

Lavretsky, H, Reinlieb, M, St Cyr, N, et al. (2015). Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry, 172, 561–569.Google Scholar

Lenze, EJ, Mulsant, BH, Shear, MK, et al. (2005). Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry, 162, 146–150.Google Scholar

Lenze, EJ, Rollman, BL, Shear, MK, et al. (2009). Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. JAMA, 301, 295–303.Google Scholar

Lenze, EJ, Mulsant, BH, Blumberger, DM, et al. (2015). Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet, 386(10011), 2404–2412.Google Scholar

Lieberman, JA, III (2004). Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry, 6(Suppl 2), 20–23.Google Scholar PubMed

Lin, FY, Chen, PC, Liao, CH, Hsieh, YW, Sung, FC (2014). Retrospective population cohort study on hip fracture risk associated with zolpidem medication. Sleep, 37, 673–679.Google Scholar

Lindeman, R, Tobin, J, Shock, N (1985). Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc, 33, 278–285.Google Scholar

Lipscombe, LL, Lévesque, L, Gruneir, A, et al. (2009). Antipsychotic drugs and hyperglycemia in older patients with diabetes. Arch Intern Med, 169, 1282–1289.Google Scholar

MacQueen, GM, Frey, BN, Ismail, Z, et al.; CANMAT Depression Work Group (2016). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly. Can J Psychiatry, 61, 588–603.Google Scholar

Madhusoodanan, S, Zaveri, D (2010). Paliperidone use in the elderly. Curr Drug Saf, 5, 149–152.Google Scholar

Maneeton, N, Maneeton, B, Woottiluk, P, et al. (2016). Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther, 10, 259–276.Google Scholar

Maust, DT, Kim, HM, Seyfried, LS (2015). Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry, 72, 438–445.Google Scholar

Mezuk, B, Morden, NE, Ganoczy, D, Post, EP, Kilbourne, AM (2010). Anticonvulsant use, bipolar disorder, and risk of fracture among older adults in the Veterans Health Administration. Am J Geriatr Psychiatry, 18, 245–255.Google Scholar

Michelson, D, Snyder, E, Paradis, E, et al. (2014). Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol, 13, 461–471.Google Scholar

Mizuno, Y, Suzuki, T, Nakagawa, A, et al. (2014). Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull, 40, 1385–1403.CrossRef Google Scholar PubMed

Møller, M, Jakobsen, S, Gjedde, A (2007). Parametric and regional maps of free serotonin 5HT1A receptor sites in human brain as function of age in healthy humans. Neuropsychopharmacology, 32, 1707–1714.Google Scholar

Montgomery, S, Chatamra, K, Pauer, L, Whalen, E, Baldinetti, F (2008). Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry, 193, 389–394.Google Scholar

Morgan, DG, May, PC, Finch, CE (1987). Dopamine and serotonin systems in human and rodent brain: effects of age and neurodegenerative disease. J Am Geriatr Soc, 35, 334–345.Google Scholar

Musselman, DL, Tomer, A, Manatunga, AK, et al. (1996). Exaggerated platelet reactivity in major depression. Am J Psychiatry, 153, 1313–1317.Google Scholar

Nurmi-Lüthje, I, Kaukonen, JP, Lüthje, P, et al. (2006). Use of benzodiazepines and benzodiazepine-related drugs among 223 patients with an acute hip fracture in Finland: comparison of benzodiazepine findings in medical records and laboratory assays. Drugs Aging, 23, 27–37.Google Scholar

O’Connor, DW, Sierakowski, C, Chin, LF, Singh, D (2010). The safety and tolerability of clozapine in aged patients: a retrospective clinical file review. World J Biol Psychiatry, 11, 788–791.Google Scholar

Ormhøj, SS, Pottegård, A, Gasse, C, Rasmussen, L (2018). Use of attention-deficit/hyperactivity disorder medication among older adults in Denmark. Br J Clin Pharmacol, 84, 1505–1513. doi:10.1111/bcp.13569.Google Scholar

Ortega, V, Tabet, N, Nilforooshan, R, Howard, R (2017). Efficacy of antidepressants for depression in Alzheimer’s disease: systematic review and meta-analysis. J Alzheimers Dis, 58, 725–733.Google Scholar

Pridan, S, Swartz, M, Baruch, Y, et al. (2015). Effectiveness and safety of clozapine in elderly patients with chronic resistant schizophrenia. Int Psychogeriatr, 27, 131–134.Google Scholar

Prince, M, Bryce, R, Albanese, E (2013). The global prevalence of dementia: a systematic review and meta-analysis. Alzheimers Dement (N Y), 9, 63–75.Google Scholar

Punyawudho, B, Ramsay, ER, Brundage, RC, et al. (2012). Population pharmacokinetics of carbamazepine in elderly patients. Ther Drug Monit, 34, 176–181.Google Scholar

Qirjazi, E, McArthur, E, Nash, DM, et al. (2016). Risk of ventricular arrhythmia with citalopram and escitalopram: a population-based study. PLoS One, 11(8), e0160768.Google Scholar

Raskin, J, Wiltse, CG, Siegal, A, et al. (2007). Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry, 164, 900–909.Google Scholar

Regier, DA, Boyd, JH, Burke, JD Jr, et al. (1988). One-month prevalence of mental disorders in the United States. Based on five epidemiologic catchment area sites. Arch Gen Psychiatry, 45, 977–986.Google Scholar

Rehman, HU, Masson, EA (2001). Neuroendocrinology of ageing. Age Ageing, 30, 279–287.CrossRef Google Scholar PubMed

Rej, S, Herrmann, N, Shulman, K, et al. (2016). Farewell mood stabilizers? Current psychotropic medication prescribing patterns in late-life bipolar disorder. Am J Geriatr Psychiatry, 24(3 Suppl), S86–S87.Google Scholar

Rinne, JO (1987). Muscarinic and dopaminergic receptors in ageing human brain. Brain Res, 404, 161–168.Google Scholar

Rosenberg, PB, Drye, LT, Martin, BK, et al.; DIADS-2 Research Group (2010). Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry, 18, 136–145.Google Scholar

Roth, M, Mountjoy, CQ, Amrein, R (1996). Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br J Psychiatry, 168, 149–157.Google Scholar

Rudolph, JL, Salow, MJ, Angelini, MC, McGlinchey, RE (2008). The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med, 168, 508–513.Google Scholar

Sabesan, P, Lankappa, S, Khalifa, N, et al. (2015). Transcranial magnetic stimulation for geriatric depression: promises and pitfalls. World J Psychiatry, 5(2), 170–181.Google Scholar

Sajatovic, M, Coconcea, N, Ignacio, RV, et al. (2008). Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. J Clin Psychiatry, 69, 41–46.Google Scholar

Sajatovic, M, Strejilevich, SA, Gildengers, AG, et al. (2015). A report on older-age bipolar disorder from the International Society for Bipolar Disorders Task Force. Bipolar Disord, 17, 689–704.Google Scholar

Sajatovic, M, Forester, BP, Tsai, J, et al. (2016). Efficacy of lurasidone in adults aged 55 years and older with bipolar depression: post hoc analysis of 2 double-blind, placebo-controlled studies. J Clin Psychiatry, 77(10), e1324–e1331.Google Scholar

Schatzberg, AF, Kremer, C, Rodrigues, HE, Murphy, GM Jr (2002). Mirtazapine vs. Paroxetine Study Group. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry, 10, 541–550.Google Scholar

Schneider, LS, Nelson, JC, Clary, CM, et al.; Sertraline Elderly Depression Study Group (2003). An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry, 160, 1277–1285.Google Scholar

Shroeck, J, Ford, J, Conway, EL, et al. (2016). Review of safety and efficacy of sleep medicines in older adults. Clin Ther, 38, 2340–2372.Google Scholar

Singh, S, Bajorek, B (2015). Pharmacotherapy in the ageing patient: the impact of age per se (a review). Ageing Res Rev, 24(Pt B), 99–110.Google Scholar

Sommer, BR, Fenn, HH (2010). Review of topiramate for the treatment of epilepsy in elderly patients. Clin Interv Aging, 5, 89–99.Google Scholar

Stage, KB, Kragh-Sørensen, PB; Danish University Antidepressant Group (2002). Age-related adverse drug reactions to clomipramine. Acta Psychiatr Scand, 105, 55–59.Google Scholar

Stranks, EK, Crowe, SF (2014). The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis. J Clin Exp Neuropsychol, 36, 691–700.Google Scholar

Tedeschini, E, Levkovitz, Y, Iovieno, N, et al. (2011). Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry, 72, 1660–1668.Google Scholar

Terzano, MG, Rossi, M, Palomba, V, Smerieri, A, Parrino, L (2003). New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf, 26, 261–282.Google Scholar

Thomas, RE (1998). Benzodiazepine use and motor vehicle accidents. Systematic review of reported association. Can Fam Physician, 44, 799–808.Google Scholar

Thorlund, K, Druyts, E, Wu, P, et al. (2015). Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc, 63, 1002–1009.Google Scholar

Tzimos, A, Samokhvalov, V, Kramer, M, et al. (2008). Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry, 16, 31–43.Google Scholar

Vestergaard, P, Rejnmark, L, Mosekilde, L (2006). Fracture risk associated with the use of morphine and opiates. J Intern Med, 260, 76–87.Google Scholar

Waade, RB, Hermann, M, Moe, HL, Molden, E (2014). Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. Eur J Clin Pharmacol, 70, 933–940.Google Scholar

Wegner, I, Wilhelm, AJ, Sander, JW, Lindhout, D (2013). The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. Epilepsy Behav, 29, 217–221.Google Scholar

Weihs, KL, Settle, EC Jr, Batey, SR, et al. (2000). Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry, 61, 196–202.Google Scholar

Wildiers, H, Highley, MS, de Bruijn, EA, van Oosterom, AT (2003). Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet, 42, 1213–1242.Google Scholar

Young, RC, Mulsant, BH, Sajatovic, M, et al.; GERI-BD Study Group (2017). GERI-BD: a randomized double-blind controlled trial of lithium and divalproex in the treatment of mania in older patients with bipolar disorder. Am J Psychiatry, 174, 1086–1093.Google Scholar

Zolezzi, M (2016). Medication management during electroconvulsant therapy. Neuropsychiatr Dis Treat, 12, 931–939.Google Scholar

References

American College of Obstetricians and Gynecologists (2008). ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists number 92, April 2008. Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol, 111, 1001–1020.Google Scholar

Baldwin, D, Wieck, A (2018). Withdrawal of, and alternatives to, valproate-containing medicines in girls and women of childbearing potential who have a psychiatric illness. Royal College of Psychiatrists, PS 04/18. Available at: www.bap.org.uk/pdfs/PS04-18-December2018.pdf (last accessed 15.8.19).Google Scholar

Bauer, A, Paronage, M, Knapp, M, et al. (2014). The Costs of Perinatal Mental Health Problems. The London School of Economics, Personal Social Services Research Unit. Available at: http://eprints.lse.ac.uk/59885/1/__lse.ac.uk_storage_LIBRARY_Secondary_libfile_shared_repository_Content_Bauer%2C%20M_Bauer_Costs_perinatal_%20mental_2014_Bauer_Costs_perinatal_mental_2014_author.pdf (last accessed 8.9.19).Google Scholar

Bennett, PN (1996). Use of monographs in drugs. In Bennett, PN, ed., Drugs and Human Lactation. Amsterdam: Elsevier Science Publishers, pp. 67–74.Google Scholar

Bodén, R, Lundgren, M, Brandt, L, et al. (2012). Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry, 69, 715–721.Google Scholar

Bonari, L, Koren, G, Einarson, TR, et al. (2005). Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making. Arch Womens Ment Health, 8(4), 214–220.Google Scholar

Boyle, B, Garne, E, Loane, M, et al. (2017). The changing epidemiology of Ebstein’s anomaly and its relationship with maternal mental health conditions: a European registry-based study. Cardiol Young, 27(4), 677–685. doi:10.1017/S1047951116001025.Google Scholar

Bromley, R, Baker, GA (2017). Fetal antiepileptic drug exposure and cognitive outcomes. Seizure, 44, 225–231.Google Scholar

Bromley, R, Weston, J, Adab, N, et al. (2014). Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev, (10), CD010236. doi:10.1002/14651858.CD010236.pub2.Google Scholar

Casanova Dias, M, Jones, I (2016). Perinatal psychiatry. Medicine, 44(12), 720–723. doi:http://dx.doi.org/10.1016/j.mpmed.2016.09.006.Google Scholar

Chambers, CD, Hernandez-Diaz, S, Van Marter, LJ, et al. (2006). Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med, 354, 579–587.Google Scholar

Christensen, J, Grønborg, TK, Sørensen, MJ, et al. (2013). Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA, 309(16), 1696–1703.Google Scholar

Cohen, LS, Altshuler, LL, Harlow, BL, et al. (2006). Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA, 295, 499–507.Google Scholar

Coughlin, CG, Blackwell, KA, Bartley, C, et al. (2015). Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol, 125(5), 1224–1235. doi:10.1097/AOG.0000000000000759.Google Scholar

Croen, LA, Grether, JK, Yoshida, CK, et al. (2011). Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry, 68, 1104–1112.Google Scholar

Dayan, J, Gaignic-Philippe, R, Seligmann, C, et al. (2011). Use of antipsychotics and breastfeeding. Curr Wom Health Rev, 7, 37–45.Google Scholar

Deligiannidis, KM, Byatt, N, Freeman, MP (2014). Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. J Clin Psychopharmacol, 34(2), 244–255. doi:10.1097/JCP.0000000000000087.Google Scholar

Di Florio, A, Forty, L, Gordon-Smith, K, et al. (2013). Perinatal episodes across the mood disorder spectrum. JAMA Psychiatry, 70(2), 168–175.Google Scholar

European Medicines Agency (2014). CMDh agrees to strengthen warnings on the use of valproate medicines in women and girls. Press release, 21 November 2014. Available at: www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Valproate_and_related_substances_31/Position_provided_by_CMDh/WC500177637.pdf (last accessed 15.8.19).Google Scholar

European Medicines Agency (2018). New measures to avoid valproate exposure in pregnancy endorsed. Press release, 23 March 2018. Available at: www.ema.europa.eu/docs/en_GB/document_library/Press_release/2018/03/WC500246391.pdf (last accessed 15.8.19).Google Scholar

Furu, K, Kieler, H, Haglund, B, et al. (2015). Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ, 350, h1798. doi:10.1136/bmj.h1798.Google Scholar

Gentile, S (2008). Infant safety with antipsychotic therapy in breast-feeding: a systematic review. J Clin Psychiatry, 69(4), 666–673.Google Scholar

Grigoriadis, S, VonderPorten, EH, Mamisashvili, L, et al. (2013). The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry, 74, e309–e320.Google Scholar

Grzeskowiak, LE, Morrison, JL, Henriksen, TB, et al. (2015). Prenatal antidepressant exposure and child behavioural outcomes at 7 years of age: a study within the Danish National Birth Cohort. BJOG, 123, 1919–1928.Google Scholar

Habermann, F, Fritzsche, J, Fuhlbrück, F, et al. (2013). Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol, 33(4), 453–462. doi:10.1097/JCP.0b013e318295fe12.Google Scholar

Hale, T (2012). Medications and Mother’s Milk. Amarillo: Hale Publishing.Google Scholar

Huybrechts, KF, Bateman, BT, Palmsten, K, et al. (2015). Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA, 313, 2142–2151.Google Scholar

Huybrechts, KF, Hernández-Díaz, S, Patorno, E, et al. (2016). Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry, 73(9), 938–946. doi:10.1001/jamapsychiatry.2016.1520.Google Scholar

Hummels, H, Bertholee, D, van der Meer, D, et al. (2016). The quality of lactation studies including antipsychotics. Eur J Clin Pharmacol, 72(12), 1417–1425.Google Scholar

Jentink, J, Loane, MA, Dolk, H, et al.; EUROCAT Antiepileptic Study Working Group (2010). Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med, 362(23), 2185–2193.Google Scholar

Jimenez-Solem, E, Andersen, JT, Petersen, M, et al. (2013). Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort study. PLoS One, 8(4), e63034. doi:10.1371/journal.pone.0063034.Google Scholar

Jones, I, Chandra, PS, Dazzan, P, Howard, LM (2014). Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period. Lancet, 384(9956), 1789–1799.Google Scholar

Källén, BA, Otterblad, OP (2007). Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol, 79, 301–308.Google Scholar

Kanes, S, Colquhoun, H, Gunduz-Bruce, H, et al. (2017). Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet, 390(10093), 480–489.Google Scholar

Koren, G, Pariente, G (2018). Pregnancy-associated changes in pharmacokinetics and their clinical implications. Pharm Res, 35(3), 61. doi:10.1007/s11095-018-2352-2.Google Scholar

Malm, H, Artama, M, Gissler, M, et al. (2011). Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol, 118, 111–120.Google Scholar

Man, KK, Tong, HH, Wong, LY, et al. (2015). Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: a systematic review and meta-analysis of observational studies. Neurosci Biobehav Rev, 49, 82–89.Google Scholar

McCrea, RL, Nazareth, I, Evans, SJ, et al. (2015). Lithium prescribing during pregnancy: a UK primary care database study. PLoS One, 10(3), e0121024. doi:10.1371/journal.pone.0121024.Google Scholar

McKnight, RF, Adida, M, Budge, K, et al. (2012). Lithium toxicity profile: a systematic review and meta-analysis. Lancet, 379(9817), 721–728. doi:10.1016/S0140-6736(11)61516-X.Google Scholar

Meador, K, Reynolds, MW, Crean, S, et al. (2008). Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res, 81(1), 1–13. doi:10.1016/j.eplepsyres.2008.04.022.Google Scholar

Meltzer-Brody, S, Howard, LM, Bergink, V, et al. (2018). Postpartum psychiatric disorders. Nat Rev Dis Primers, 4, 18022. doi:10.1038/nrdp.2018.22.Google Scholar

Myles, N, Newall, H, Ward, H, et al. (2013). Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust N Z J Psychiatry, 47(11), 1002–1012. doi:10.1177/0004867413492219.Google Scholar

National Institute for Health and Care Excellence (NICE) (2014). Antenatal and postnatal mental health – clinical management and service guidance. Clinical guideline [CG192]. London: National Institute for Health and Care Excellence.Google Scholar

Patorno, E, Huybrechts, KF, Bateman, BT, et al. (2017). Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med, 376(23), 2245–2254. doi:10.1056/NEJMoa1612222.Google Scholar

Peng, M, Gao, K, Ding, Y, et al. (2013). Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. Psychopharmacology (Berl), 228(4), 577–584. doi:10.1007/s00213-013-3060-6.Google Scholar

Petersen, I, McCrea, RL, Osborn, DJ, et al. (2014). Discontinuation of antipsychotic medication in pregnancy: a cohort study. Schizophr Res, 159(1), 218–225. doi:10.1016/j.schres.2014.07.034.Google Scholar

Ross, LE, Grigoriadis, S, Mamisashvili, L, et al. (2013). Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry, 70, 436–443.Google Scholar

Royal College of Psychiatrists, Centre for Care Quality Improvement (2016). Topic 15a baseline audit report. Prescribing valproate for bipolar disorder. Available at: www.covwarkpt.nhs.uk/download.cfm?doc=docm93jijm4n2406.pdf&ver=3039 (last accessed 15.8.19).Google Scholar

Schou, M (1976). What happened later to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr Scand, 54(3), 193–197.Google Scholar

Stein, A, Pearson, RM, Goodman, SH, et al. (2014). Effects of perinatal mental disorders on the fetus and child. Lancet, 384(9956), 1800–1819. http://dx.doi.org/10.1016/S0140-6736(14)61277–0.Google Scholar

Tomson, T, Battino, D (2012). Teratogenic effects of antiepileptic drugs. Lancet Neurol, 11(9), 803–813. doi:10.1016/S1474-4422(12)70103-5.Google Scholar

Toxnet – LactMed (2019). Drugs and Lactation Database – LactMed. Available at: https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm (last accessed 8.9.19).Google Scholar

Veroniki, AA, Cogo, E, Rios, P, et al. (2017a). Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med, 15(1), 95. doi:10.1186/s12916-017-0845-1.Google Scholar

Veroniki, AA, Rios, P, Cogo, E, et al. (2017b). Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. BMJ Open, 7(7), e017248. doi:10.1136/bmjopen-2017-017248.Google Scholar

Viktorin, A, Uher, R, Reichenberg, A, et al. (2017). Autism risk following antidepressant medication during pregnancy. Psychol Med, 47, 2787–2796. doi:10.1017/S0033291717001301.Google Scholar

Wesseloo, R, Wierdsma, AI, van Kamp, IL, et al. (2017). Lithium dosing strategies during pregnancy and the postpartum period. Br J Psychiatry, 211(1), 31–36. doi:10.1192/bjp.bp.116.192799.Google Scholar

Westin, AA, Brekke, M, Molden, E, et al. (2018). Treatment with antipsychotics in pregnancy: changes in drug disposition. Clin Pharmacol Ther, 103(3), 477–484. doi:10.1002/cpt.770.Google Scholar

Wieck, A (2017). Prevention of bipolar episodes with lithium in the perinatal period. Br J Psychiatry, 211, 3–4.Google Scholar

Wlodarczyk, BJ, Palacios, AM, George, TM, et al. (2012). Antiepileptic drugs and pregnancy outcomes. Am J Med Genet A, 158A(8), 2071–2090. doi:10.1002/ajmg.a.35438.Google Scholar

Yonkers, KA, Gotman, N, Smith, MV, et al. (2011). Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiology, 22, 848–854.Google Scholar

References

Abdulrahim, D, Bowden-Jones, O, on behalf of the NEPTUNE Expert Group (2015). Guidance on the Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances. London: Novel Psychoactive Treatment UK Network (NEPTUNE).Google Scholar

Alexander, J, Tharyan, P, Adams, C, et al. (2004). Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. Br J Psychiatry, 185, 63–69.Google Scholar

Andrezina, R, Josiassen, RC, Marcus, RN, et al. (2006). Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology, 188, 281–292.Google Scholar

Azeem, MW, Aujla, A, Rammerth, M, Binsfeld, G, Jones, RB (2011). Effectiveness of six core strategies based on trauma informed care in reducing seclusions and restraints at a child and adolescent psychiatric hospital. J Child Adolesc Psychiatr Nurs, 24, 11–15. https://doi.org/10.1111/j.1744–6171.2010.00262.x.Google Scholar

Bowers, L (2014). Safewards: a new model of conflict and containment on psychiatric wards. J Psychiatr Ment Health Nurs, 21, 499–508.Google Scholar

Bowers, L, Stewart, D, Papadopoulos, C, et al. (2011). Inpatient Violence and Aggression: A Literature Review. London: Institute of Psychiatry, King’s College London.Google Scholar

Bowers, L, James, K, Quirk, A, et al. (2015). Reducing conflict and containment rates on acute psychiatric wards: the Safewards cluster randomised controlled trial. Int J Nurs Stud, 52, 1412–1422. https://doi.org/10.1016/j.ijnurstu.2015.05.001.Google Scholar

Breier, A, Meehan, K, Birkett, M, et al. (2002). A double-blind, placebo-controlled dose response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry, 59, 441–448.Google Scholar

Canadian Agency for Drugs and Technologies in Health (CADTH) (2015). Use of Antipsychotics and/or Benzodiazepines as Rapid Tranquilization in In-Patients of Mental Facilities and Emergency Departments: A Review of the Clinical Effectiveness and Guidelines. CADTH Rapid Response Reports.Google Scholar

Chin, CN, Hamid, ARA, Philip, G, et al. (1998). A double-blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics. Med J Malaysia, 53(4), 365–371.Google Scholar

Citrome, L (2012). Inhaled loxapine for agitation revisited: focus on effect sizes 2 from Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. Int J Clin Pract, 66, 318–325. https://doi.org/10.1111/j.1742–1241.2011.02890.x.Google Scholar

Cole, JB, Moore, JC, Nystrom, PC, et al. (2016). A prospective study of ketamine versus haloperidol for severe prehospital agitation. Clin Toxicol (Phila), 54, 556–562.Google Scholar

Department of Health (DH) (2014). Positive and Proactive Care: Reducing the Need for Restrictive Interventions. London: Department of Health. Available at: www.gov.uk/government/publications/positive-and-proactive-care-reducing-restrictive-interventions (last accessed 15.8.19).Google Scholar

Department of Health (DH) (2015). Mental Health Act 1983: Code of Practice. London: The Stationery Office. Available at: www.gov.uk/government/uploads/system/uploads/attachment_data/file/435512/MHA_Code_of_Practice.PDF (last accessed 15.8.19).Google Scholar

Douglas-Hall, P, Whicher, EV (2015). ‘As required’ medication regimens for seriously mentally ill people in hospital. Cochrane Database Syst Rev, (12), CD003441. https://doi.org/10.1002/14651858.CD003441.pub3.Google Scholar

eMC (2017). Summary of Product Characteristics (updated January 2017): Clopixol Acuphase Injection. Available at: www.medicines.org.uk/emc/medicine/1071 (last accessed 15.8.19).Google Scholar

Galbally, M, Snellen, M, Lewis, A (2014). Psychopharmacology and Pregnancy. New York: Springer. https://doi.org/10.1007/978–3-642–54562-7.Google Scholar

Garriga, M, Pacchiarotti, I, Kasper, S, et al. (2016). Assessment and management of agitation in psychiatry: expert consensus. World Biol Psychiatry, 17(2), 86–128. https://doi.org/10.3109/15622975.2015.1132007.Google Scholar

Gaskin, CJ, Elsom, SJ, Happell, B (2007). Interventions for reducing the use of seclusion in psychiatric facilities. Br J Psychiatry, 191, 298–303. https://doi.org/10.1192/bjp.bp.106.034538.Google Scholar

Gillies, D, Sampson, S, Beck, A, Rathbone, J (2013). Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev, (4), CD003079. https://doi.org/10.1002/14651858.CD003079.pub3.Google Scholar

Gillings, M, Grundlingh, J, Aw-Yong, M (2016). Guidelines for the Management of Excited Delirium/Acute Behavioural Disturbance (ABD). London: The Royal College of Emergency Medicine, Best Practice Guidance.Google Scholar

Hardy, S, Bennett, L, Rosen, P, et al. (2017). The feasibility of using body worn cameras in an inpatient mental health setting. Ment Health Fam Med, 357, 393–400.Google Scholar

Hodgins, S, Alderton, J, Cree, A, Aboud, A, Mak, T (2007). Aggressive behaviour, victimisation and crime among severely mentally ill patients requiring hospitalisation. Br J Psychiatry, 191, 343–350. https://doi.org/10.1192/bjp.bp.106.06.029587.Google Scholar

Huckshorn, KA (2006). Six Core Strategies for Reducing Seclusion and Restraint Use: A Snapshot of Six Core Strategies for the Reduction of S/R. National Association of State Mental Health Program Directors (NASMHPD). Available at: www.nasmhpd.org/sites/default/files/ConsolidatedSixCore StrategiesDocument.pdf (last accessed 15.8.19).Google Scholar

Huf, G, Countinho, ESF, Adams, CE; TREC Collaborative Group (2007). Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine. BMJ, 335, 869. https://doi.org/10.1136/bmj.39339.448819.AE.Google Scholar

Huf, G, Alexander, J, Gandhi, P, Allen, MH (2016). Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database of Syst Rev, (11), CD005146. https://doi.org/10.1002/14651858.CD005146.pub3.Google Scholar

Innes, J, Sethi, F (2012). Current rapid tranquillisation documents in the UK: a review of the drugs recommended, their routes of administration and clinical parameters influencing their use. J Psychiatr Intensive Care, 9, 110–118. https://doi.org/10.1017/S174264641200026X.Google Scholar

Jayakody, K, Gibson, RC, Kumar, A, Gunadasa, S (2012). Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database Syst Rev, (4), CD000525. https://doi.org/10.1002/14651858.CD000525.pub3.Google Scholar

Kerr, I, Taylor, D (1997). Acute disturbed or violent behaviour: principals of treatment. J Psychopharmacology, 11, 271–277.Google Scholar

Khwaja, M, Beer, D (eds.) (2013). Prevention and Management of Violence: Guidance for Mental Healthcare Professionals. College Report CR177. London: Royal College of Psychiatrists.Google Scholar

Krug, EG, Dahlberg, LL, Mercy, JA, Zwi, AB, Lozano, R (eds.) (2002). World report on violence and health. Geneva: World Health Organization.Google Scholar

Kwentus, J, Riesenberg, RA, Marandi, M, et al. (2012). Rapid acute treatment of agitation in patients with bipolar I disorder: a multicentre, randomized, placebo-controlled trial with inhaled loxapine. Bipolar Disord, 14, 31–40. https://doi.org/10.1111/j.1399–5618.2011.00975.x.Google Scholar

Lesem, MD, Tran-Johnson, TK, Riesenberg, RA, et al. (2011). Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled trial of inhaled loxapine. Br J Psychiatry, 198, 51–58. https://doi.org/10.1192/bjp.bp.110.081513.Google Scholar

Lingford-Hughes, L, Welch, W, Peters, L, Nutt, D; British Association for Psychopharmacology Expert Reviewers Group (2012). BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol, 26(7), 899–952. https://doi.org/10.1177/0269881112444324.Google Scholar

Lukens, TW, Wolf, SJ, Edlow, JA, et al. (2006). Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department. Ann Emerg Med, 47, 79–99.Google Scholar

Martel, M, Sterzinger, A, Miner, J, Clinton, J, Biros, M (2005). Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. Acad Emerg Med, 12(12), 1167–1172.Google Scholar

McAllister-Williams, RH, Baldwin, DS, Cantwell, R, et al. (2017). British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol, 31(5), 519–552. https://doi.org/10.1177/0269881117699361.Google Scholar

NASMHPD (2008). Six Core Strategies to Reduce Seclusion and Restraint Use. Alexandria, VA: National Association of State Mental Health Program Directors. Available at: www.nasmhpd.org/sites/default/files/Consolidated%20Six%20Core%20Strategies%20Document.pdf (last accessed 15.8.19).Google Scholar

National Institute of Health and Clinical Excellence (NICE) (2005). Violence: the short-term management of disturbed and violent behaviour in inpatient psychiatric settings and emergency departments. Clinical guideline [CG25]. London: National Institute for Health and Care Excellence.Google Scholar

National Institute for Health and Care Excellence (NICE) (2015). Violence and aggression: short-term management in mental health, health and community settings. NICE guideline [NG10]. London: National Institute for Health and Care Excellence. Available at: http://nice.org.uk/guidance/ng10 (last accessed 15.8.19).Google Scholar

National Institute for Health and Care Excellence (NICE) (2017). Violent and Aggressive Behaviours in People with Mental Health Problems. Quality Standard [QS154]. London: National Institute for Health and Care Excellence. Available at: www.nice.org.uk/guidance/qs154 (last accessed 15.8.19).Google Scholar

Patel, MX, Sethi, FN, Barnes, TRE, et al. (2018). Joint BAP NAPICU evidence based consensus guidelines for the clinical management of acute disturbance: de-escalation and rapid tranquillisation. J Psychopharmacol, 32(6), 601–640. [This article was also co-published in the Journal of Psychiatric Intensive Care]Google Scholar

POMH-UK (2017). Topic 16a. Rapid tranquillisation in the context of the pharmacological management of acutely-disturbed behaviour. London: Royal College of Psychiatrists, CCQI263.Google Scholar

Price, O, Baker, J, Bee, P, Lovell, K (2015). Learning and performance outcomes of mental health staff training in de-escalation techniques for the management of violence and aggression. Br J Psychiatry, 206, 447–455. https://doi.org/10.1192/bjp.bp.114.144576.Google Scholar

Raveendran, N, Tharyan, P, Alexander, J, Adams, CE; TREC-India II Collaborative Group (2007). Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. BMJ, 335, 865. https://doi.org/10.1136/bmj.39341.608519.BE.Google Scholar

Royal College of Psychiatrists (RCPsych) (2014). Consensus Statement on High-Dose Antipsychotic Medication. College Report CR190. London: Royal College of Psychiatrists.Google Scholar

Taylor, D, McConnell, D, McConnell, H, Abel, K, Kerwin, R (1999). The Bethlem and Maudsley NHS Trust Prescribing Guidelines 1999, 5th ed. London: Martin Dunitz.Google Scholar

Taylor, D, McConnell, DH, McConnell, D, Kerwin, R (2001). Maudsley 2001 Prescribing Guidelines, 6th ed. London: Martin Dunitz.Google Scholar

Taylor, D, Okocha, C, Paton, C, Smith, S, Connolly, A (2008). Buccal midazolam for agitation on psychiatric intensive care wards. Int J Psychiatry Clin Pract, 12(4), 309–311. https://doi.org/10.1080/13651500802233886.Google Scholar

Taylor, D, Paton, C, Kapur, S (2015). The Maudsley Prescribing Guidelines in Psychiatry, 12th ed. West Sussex: Wiley Blackwell.Google Scholar

Taylor, D, Barnes, TRE, Young, AH (2018). The Maudsley Prescribing Guidelines in Psychiatry, 13th ed. Hoboken: Wiley Blackwell.Google Scholar

Tran-Johnson, TK, Sack, DA, Marcus, RN, et al. (2007). Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry, 68, 111–119.Google Scholar

TREC Collaborative Group (2003). Rapid tranquillisation for agitated patients in psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ, 327, 708–711. https://doi.org/10.1136/bmj.327.7417.708.Google Scholar

Wilson, MP, Pepper, D, Currier, GW, Holloman, GH Jr, Feifel, D (2012). The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project Beta Psychopharmacology Workgroup. West J Emerg Med, 13, 26–34. https://doi.org/10.5811/westjem.2011.9.6866.Google Scholar

Wright, P, Birkett, M, David, SR, et al. (2001). Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry, 158(7), 1149–1151.Google Scholar

Zaman, H, Sampson, SJ, Beck, ALS, et al. (2017). Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev, (12), CD003079.Google Scholar

Zimbroff, DL, Marcus, RN, Manos, G, et al. (2007). Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacology, 27, 171–176.Google Scholar

References

Alberti, KGMM, Eckel, RH, Grundy, SM, et al. (2009). Harmonizing the metabolic syndrome. Circulation, 120, 1640–1645.Google Scholar

Allison, DB, Mentore, JL, Heo, M, et al. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry, 156, 1686–1696.Google Scholar

Aronne, LJ, Wadden, T, Isoldi, KK, et al. (2009). When prevention fails, obesity treatment strategies. Am J Med, 122(4 Suppl 1), S24–S32.Google Scholar

Arranz, B, Rosel, P, Ramirez, N, et al. (2004). Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry, 65, 1335–1342.Google Scholar

Barnes, TRE, Mutsatsa, SH, Hutton, SB, et al. (2006). Comorbid substance use and age of onset in schizophrenia: the West London first episode study. Br J Psychiatry, 188, 237–242.Google Scholar

Barnes, TRE, Paton, C, Cavanagh, M-R; UK Prescribing Observatory for Mental Health (2007). A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull, 33, 1397–1403.Google Scholar

Barnes, TRE, Bhatti, SF, Adroer, R, et al. (2015). Screening for the metabolic side effects of antipsychotic medication: findings from a 6-year quality improvement programme in the UK. BMJ Open, 5, e007633.Google Scholar

Barr, RS, Culhane, MA, Jubelt, LE, et al. (2008). The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology, 33, 480–490.Google Scholar

Bartoli, F, Crocamo, C, Clerici, M, et al. (2015). Second-generation antipsychotics and adiponectin levels in schizophrenia: a comparative meta-analysis. Eur Neuropsychopharmacol, 25, 1767–1774.Google Scholar

Bennett, ME, Wilson, AL, Genderson, M, et al. (2013). Smoking cessation in people with schizophrenia. Curr Drug Abuse Rev, 13, 180–190.Google Scholar

Bobo, WV, Cooper, WO, Stein, M, et al. (2013). Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry, 70, 1067–1075.Google Scholar

Breese, CR, Lee, MJ, Adams, CE, et al. (2000). Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology, 23, 351–364.Google Scholar

Brown, S (1997). Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry, 171, 502–508.Google Scholar

Bruins, J, Jorg, F, Bruggeman, R, et al. (2014). The effects of lifestyle interventions on (long-term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders, a meta-analysis. PLoS One, 9, e112276.Google Scholar

Bushe, CJ, Slooff, CJ, Haddad, PM, Karagianis, JL (2012). Weight change from 3-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database. J Clin Psychiatry, 73(6), e749–e755.Google Scholar

Caemmerer, J, Correll, CU, Maayan, L (2012). Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res, 140, 159–168.Google Scholar

Chiu, C, Chen, C, Chen, B, et al. (2010). The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry, 34, 866–870.Google Scholar

Clifton, PG, Rusk, IN, Cooper, SJ (1991). Effects of dopamine D1 and dopamine D2 antagonists on the free feeding and drinking patterns of rats. Behav Neurosci, 105, 272–281.Google Scholar

Connolly, V, Unwin, N, Sherriff, P, et al. (2000). Diabetes prevalence and socioeconomic status, a population based study showing increased prevalence of type 2 diabetes mellitus in deprived areas. J Epidemiol Community Health, 54, 173–177.Google Scholar

Cooper, SJ, Reynolds, GP, Barnes, TRE, et al. (2016). BAP guidelines on the management of weight gain and metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol, 30, 717–748.Google Scholar

Correll, CU, Manu, P, Olshanskiy, V, et al. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA, 302(16), 1765–1773.Google Scholar

Correll, CU, Robinson, DG, Schooler, NR (2014). Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders. JAMA Psychiatry, 71, 1350–1363.Google Scholar

Daumit, GL, Goldberg, RW, Anthony, C (2005). Physical activity patterns in adults with severe mental illness. J Nerv Ment Dis, 193, 641–646.Google Scholar

Daumit, GL, Goff, DC, Meyer, JM, et al. (2008). Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res, 105, 175–187.Google Scholar

Daumit, GL, Dickerson, FB, Wang, N, et al. (2013). A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med, 368, 1594–1602.Google Scholar

De Hert, M, Dekker, JM, Wood, D, et al. (2009a). Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry, 24, 412–424.Google Scholar

De Hert, M, Schreurs, V, Vancampfort, D, et al. (2009b). Metabolic syndrome in people with schizophrenia, a review. World Psychiatry, 8, 15–22.Google Scholar

De Hert, M, Correll, CU, Bobes, J, et al. (2011). Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry, 10, 52–77.Google Scholar

Deng, C, Lian, J, Pai, N, et al. (2012). Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. J Psychopharmacol, 26, 1271–1279.Google Scholar

Department of Health (2016). Alcohol Guidelines Review – report from the guidelines development group to the UK Chief Medical Officers. London: Department of Health. Available at: www.gov.uk/government/consultations/health-risks-from-alcohol-new-guidelines (last accessed 16.8.19).Google Scholar

Dombrowsi, SU, Avenell, A, Sniehotta, FF (2010). Behavioural interventions for obese adults with additional risk factors for morbidity: systematic review of effects on behaviour, weight and disease risk factors. Obes Facts, 3, 377–396.Google Scholar

Druss, BG, Von Esenwein, SA, Glick, GE, et al. (2017). Randomized trial of an integrated behavioral health home: the Health Outcomes Management and Evaluation (HOME) study. Am J Psychiatry, 174(3), 246–255.Google Scholar

Fan, X, Borba, CPC, Copeland, P, et al. (2013). Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand, 127, 217–226.Google Scholar

Faulkner, G, Cohn, T, Remington, G, et al. (2007). Body mass index, waist circumference and quality of life in individuals with schizophrenia. Schizophr Res, 90, 174–178.Google Scholar

Fernandez-Sola, J (2015). Cardiovascular risks and benefits of moderate and heavy alcohol consumption. Nat Rev Cardiol, 12, 576–587. doi:10.1038/nrcardio.2015.91.Google Scholar

Fleischhacker, WW, Heikkinen, ME, Olie, J-P, et al. (2010). Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine, a randomized, double-blind, placebo-controlled trial. Int J Psychopharmacol, 13, 1115–1125.Google Scholar

Fleischhacker, WW, Siu, CO, Bodén, R, et al.; EUFEST study group (2013). Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int J Psychopharmacol, 16, 987–995.Google Scholar

Foley, DL, Morley, KI (2011). Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry, 68, 609–616.Google Scholar

Gafoor, R, Booth, P, Gulliford, MC (2018). Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ, 361, k1951. http://dx.doi.org/10.1136/bmj.k1951.Google Scholar

Gilbody, S, Peckham, E, Man, M-S, et al. (2015). Bespoke smoking cessation for people with severe mental ill health (SCIMITAR), a pilot randomised controlled trial. Lancet Psychiatry, 2, 395–402.Google Scholar

Hamoui, N, Kingsbury, S, Anthone, GJ, et al. (2004). Surgical treatment of morbid obesity in schizophrenic patients. Obes Surg, 14, 349–352.Google Scholar

Hasan, A, Falkai, P, Wobrock, T, et al. (2013). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia: part 2, update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry, 14, 2–44.Google Scholar

Hegedűs, C, Kovacs, D, Kiss, R, et al. (2015). Effect of long-term olanzapine treatment on meal-induced insulin sensitization and on gastrointestinal peptides in female Sprague–Dawley rats. J Psychopharmacol, 29, 1271–1279.Google Scholar

Henderson, DC, Cagliero, E, Copeland, PM, et al. (2005). Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents. Arch Gen Psychiatry, 62, 19–28.Google Scholar

Henderson, DC, Kunkel, L, Nguyen, DD, et al. (2006). An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand, 113, 142–147.Google Scholar

Henderson, DC, Fan, X, Copeland, PM, et al. (2009). Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol, 29, 165–169.Google Scholar

Hermes, E, Nasrallah, H, Davis, V, et al. (2011). The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res, 128, 166–170.Google Scholar

Hickling, LM, Perez-Iglesias, R, McNeill, A, et al. (2018). A pre-post pilot study of electronic cigarettes to reduce smoking in people with severe mental illness. Psychol Med, 49, 1033–1040. https://doi.org/10.1017/S0033291718001782.Google Scholar

Hippisley-Cox, J, Coupland, C, Brindle, P (2017). Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ, 357, j2099.Google Scholar

Hjorthoj, C, Østergaard, ML, Benros, ME, et al. (2015). Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study. Lancet Psychiatry, 2(9), 801–808.Google Scholar

Holt, RI, Mitchell, AJ. (2015). Diabetes mellitus and severe mental illness, mechanisms and clinical implications. Nat Rev Endocrinol, 11, 79–89.Google Scholar

Holt, RI, Gossage-Worrall, R, Hind, D, et al. (2019). Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial. Br J Psychiatry, 214, 63–73.Google Scholar

Hommel, JD, Trinko, R, Sears, RM, et al. (2006). Leptin receptor signaling in midbrain dopamine neurons regulates feeding. Neuron, 51, 801–810.Google Scholar

Hunt, GE, Siegfried, N, Morley, K, et al. (2013). Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev, (10), CD001088. doi:10.1002/14651858.CD001088.pub3.Google Scholar

InterAct Consortium (2014). Smoking and long-term risk of type 2 diabetes, the EPIC-InterAct study in European populations. Diabetes Care, 37, 3164–3171.Google Scholar

Ishøy, PL, Knop, FK, Broberg, BV, et al. (2017). Effect of GLP‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: a randomized, placebo‐controlled trial. Diabetes Obes Metab, 19, 162–171.Google Scholar

Jarskog, LF, Hamer, RM, Catellier, DJ, et al.; METS Investigators (2013). Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry, 170, 1032–1040.Google Scholar

Jin, H, Meyer, J, Mudaliar, S, et al. (2008). Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res, 100, 70–85.Google Scholar

Johnson, DE, Yamazaki, H, Ward, KM, et al. (2005). Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perfused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes, 54, 1552–1558.Google Scholar

Kahn, RS, Fleischhacker, WW, Boter, H (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder, an open randomised clinical trial. Lancet, 371, 1085–1097.Google Scholar

Kelly, C, McCreadie, R (2000). Cigarette smoking and schizophrenia. Adv Psychiatr Treat, 6, 327–331.Google Scholar

Kim, SF, Huang, AS, Snowman, AM, et al. (2007). From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A, 104, 3456–3459.Google Scholar

Kinon, BJ, Kaiser, CJ, Ahmed, S (2005). Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol, 25, 255–258.Google Scholar

Kirk, SL, Neill, JC, Jones, DN, et al. (2004). Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. Eur J Pharmacol, 505, 253–254.Google Scholar

Kirk, SL, Glazebrook, J, Grayson, B, et al. (2009). Olanzapine-induced weight gain in the rat, role of 5-HT2C and histamine H1 receptors. Psychopharmacology, 207, 119–125.Google Scholar

Kodama, S, Horikawa, C, Fujihara, K, et al. (2014). Quantitative relationship between body weight gain in adulthood and incident type 2 diabetes: a meta-analysis. Obes Rev, 15, 202–214.Google Scholar

Koskinen, J, Löhönen, J, Koponen, H, et al. (2009). Prevalence of alcohol use disorders in schizophrenia – a systematic review and meta-analysis. Acta Psychiatr Scand, 120, 85–96.Google Scholar

Kramer, CK, Leitao, C, Pinto, LC, et al. (2011). Efficacy and safety of topiramate on weight loss, a meta-analysis of randomized controlled trials. Obes Rev, 12, e338–e347. doi:10.1111/j.1467-789X.2010.00846.x.Google Scholar

Kroeze, WK, Hufeisen, SJ, Popadak, BA, et al. (2003). H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology, 28, 519–526.Google Scholar

Kroon, LA (2007). Drug interactions with smoking. Am J Health Syst Pharm, 64(18), 1917–1921.Google Scholar

Larsen, JR, Vedtofte, L, Jakobsen, MSL, et al. (2017). Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder a randomized clinical trial. JAMA Psychiatry, 74, 719–728.Google Scholar

Lawrence, D, Hancock, KJ, Kisely, S (2013). The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ, 346, f2539.Google Scholar

Lester, H, Marshall, M, Jones, P, et al. (2011). Views of young people in early intervention services for first-episode psychosis in England. Psychiatr Serv, 62, 882–887.Google Scholar

Leucht, S, Cipriani, A, Spineli, L, et al. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet, 382, 951–962.Google Scholar

Lingford-Hughes, AR, Welch, S, Peters, L, et al. (2012). BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity, recommendations from BAP. J Psychopharmacol, 26, 899–952.Google Scholar

Manu, P, Dima, L, Shulman, M (2015). Weight gain and obesity in schizophrenia, epidemiology, pathobiology, and management. Acta Psychiatr Scand, 132, 97–108.Google Scholar

Matsui-Sakata, A, Ohtani, H, Sawada, Y (2005). Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet, 20, 368–378.Google Scholar

McCreadie, RG; Sottish Schizophrenia Lifestyle Group (2003). Diet, smoking and cardiovascular risk in people with schizophrenia. Br J Psychiatry, 183, 534–539.Google Scholar

McManus, S, Bebbington, P, Jenkins, R, Brugha, T (eds.) (2016). Adult Psychiatric Morbidity Survey: Mental Health and Wellbeing, England, 2014. Leeds: NHS Digital.Google Scholar

McQuade, RD, Stock, E, Marcus, R, et al. (2004). A comparison of weight change during treatment with olanzapine or aripiprazole, results from a randomised, double-blind study. J Clin Psychiatry, 65, 47–56.Google Scholar

Meyer, JM, Davis, VG, McEvoy, JP, et al. (2008). Impact of antipsychotic treatment on non-fasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res, 103, 104–109.Google Scholar

Minutolo, G, Caponnetto, P, Auditore, R, et al. (2013). Management of smoking reduction and cessation in inpatients with schizophrenia: impact of electronic cigarettes. Eur Neuropsychopharmacol, 23(Suppl 2), S581–S582.Google Scholar

Mitchell, AJ, Malone, D, Doebbeling, CC (2009). Quality of medical care for people with and without comorbid mental illness and substance misuse, systematic review of comparative studies. Br J Psychiatry, 194, 491–499.Google Scholar

Mitchell, AJ, Vancampfort, D, DeHerdt, A, et al. (2013a). Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull, 39, 295–305.Google Scholar

Mitchell, AJ, Vancampfort, D, Sweers, K, et al. (2013b). Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders. A review and meta-analysis. Schizophr Bull, 39, 306–318.Google Scholar

Mizuno, Y, Suzuki, T, Nakagawa, A, et al. (2014). Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia, a systematic review and meta-analysis. Schizophr Bull, 40, 1385–1403.Google Scholar

Mothi, SS, Tandon, N, Padmanabhan, J, et al. (2015). Increased cardiometabolic dysfunction in first-degree relatives of patients with psychotic disorders. Schizophr Res, 165, 103–107.Google Scholar

Mukundan, A, Faulkner, G, Cohn, T, et al. (2010). Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev, (12), CD006629. doi:10.1002/14651858.CD006629.pub2.Google Scholar

Muscatello, MRA, Bruno, A, Pandolfo, G, et al. (2011). Effect of aripiprazole augmentation of clozapine in schizophrenia, a double-blind, placebo-controlled study. Schizophr Res, 127, 93–99.Google Scholar

Myles, N, Newall, HD, Curtis, J, et al. (2012). Tobacco use before, at, and after first-episode psychosis, a systematic meta-analysis. J Clin Psychiatry, 73, 468–475.Google Scholar

National Institute for Health and Care Excellence (NICE) (2008). Stop smoking services. Public health guideline [PH10]. London: National Institute for Health and Care Excellence.Google Scholar

National Institute for Health and Care Excellence (NICE) (2011). Alcohol-use disorders, diagnosis, assessment and management of harmful drinking and alcohol dependence. Clinical guideline [CG115]. London: National Institute for Health and Care Excellence.Google Scholar

National Institute for Health and Care Excellence (NICE) (2012). Preventing type 2 diabetes: risk identification and interventions for individuals at high risk. Public health guideline [PH38]. London: National Institute for Health and Care Excellence.Google Scholar

National Institute for Health and Care Excellence (NICE) (2014a). Psychosis and schizophrenia in adults, prevention and management. Clinical guideline [CG178]. London: National Institute for Health and Care Excellence.Google Scholar

National Institute for Health and Care Excellence (NICE) (2014b). Cardiovascular disease: risk assessment and reduction. Clinical guideline [CG181]. London: National Institute for Health and Care Excellence.Google Scholar

National Institute for Health and Care Excellence (NICE) (2014c). Bipolar disorder, assessment and management. Clinical guideline [CG185]. London: National Institute for Health and Care Excellence.Google Scholar

National Institute for Health and Care Excellence (NICE) (2014d). Obesity, identification, assessment and management. Clinical guideline [CG189]. London: National Institute for Health and Care Excellence.Google Scholar

National Institute for Health and Care Excellence (NICE) (2015). Type 2 diabetes in adults: management. NICE guideline [NG28]. London: National Institute for Health and Care Excellence.Google Scholar

Newcomer, JW (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs, 19(Suppl 1), 1–93.Google Scholar

Newcomer, JW, Haupt, DW, Fucetola, R, et al. (2002). Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry, 59, 337–345.Google Scholar

Olfson, M, Gerhard, T, Huang, C (2015). Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry, 72, 1172–1181.Google Scholar

Osborn, DPJ, Levy, G, Nazareth, I, et al. (2007a). Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s general practice research database. Arch Gen Psychiatry, 64, 242–249.Google Scholar

Osborn, DP, Nazareth, I, King, MB (2007b). Physical activity, dietary habits and coronary heart disease risk factor knowledge amongst people with severe mental illness, a cross sectional comparative study in primary care. Soc Psychiatry Psychiatr Epidemiol, 42, 787–793.Google Scholar

Osborn, D, Hardoon, S, Omar, RZ, et al. (2015). Cardiovascular risk prediction models for people with severe mental illness. Results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program. JAMA Psychiatry, 72, 143–151.Google Scholar

Padmanabhan, JL, Nanda, P, Tandon, N, et al. (2016). Polygenic risk for type 2 diabetes mellitus among individuals with psychosis and their relatives. J Psychiatr Res, 77, 52–58.Google Scholar

Perry, BI, McIntosh, G, Weich, S, et al. (2016). The association between first-episode psychosis and abnormal glycaemic control, systematic review and meta-analysis. Lancet Psychiatry, 3, 1049–1058.Google Scholar

Petrakis, IL, Nich, C, Ralevski, E (2006). Psychotic spectrum disorders and alcohol abuse, a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull, 32, 644–654.Google Scholar

Pillinger, T, Beck, K, Gobjila, C, et al. (2017). Impaired glucose homeostasis in first-episode schizophrenia, a systematic review and meta-analysis. JAMA Psychiatry, 74, 261–269.Google Scholar

Pratt, SI, Sargent, J, Daniels, L, et al. (2016). Appeal of electronic cigarettes in smokers with serious mental illness. Addict Behav, 59, 30–34.Google Scholar

Reynolds, GP (2012). The pharmacogenetics of antipsychotic drug-induced weight gain – a critical review. Clin Psychopharmacol Neurosci, 10, 71–77.Google Scholar

Reynolds, GP, Kirk, SL (2010). Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms. Pharmacol Ther, 125, 169–179.Google Scholar

Reynolds, GP, McGowan, O (2017). Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment. J Psychopharmacol, 31, 1430–1436. https//doi.org/10.1177/026988111772.Google Scholar

Reynolds, GP, Dalton, C, Watrimez, W, et al. (2019). Adjunctive lurasidone suppresses food intake and weight gain associated with olanzapine administration in rats. Clin Psychopharmacol Neurosci, 17, 314–317.Google Scholar

Roffeei, SN, Reynolds, GP, Zainal, NZ, et al. (2014). Association of ADR2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole and ziprasidone. Hum Psychopharmacol, 29, 38–45.Google Scholar

Royal College of Psychiatrists (2012). Report of the National Audit of Schizophrenia (NAS) 2012. London: Healthcare Quality Improvement Partnership.Google Scholar

Royal College of Psychiatrists (2014). Report of the second round of the National Audit of Schizophrenia (NAS) 2014. London: Healthcare Quality Improvement Partnership.Google Scholar

Royal College of Psychiatrists (2018). National Clinical Audit of Psychosis – National report for the core audit 2018. London: Healthcare Quality Improvement Partnership. Available at: www.rcpsych.ac.uk/docs/default-source/improving-care/ccqi/national-clinical-audits/ncap-library/ncap-national-report-for-core-audit-2018.pdf?sfvrsn=23c6a262_2 (last accessed 16.8.19).Google Scholar

Rummel-Kluge, C, Komossa, K, Schwarz, S, et al. (2010). Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia, a systematic review and meta-analysis. Schizophr Res, 123, 225–233.Google Scholar

Ryan, MC, Collins, P, Thakore, JH (2003). Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry, 160, 284–289.Google Scholar

Sengupta, S, Parrilla-Escobar, MA, Klink, R, et al. (2008). Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls? Schizophr Res, 102, 329–336.Google Scholar

Shiers, DE, Rafi, I, Cooper, SJ, Holt, RIG (2014). Positive Cardiometabolic Health Resource, an intervention framework for patients with psychosis and schizophrenia. 2014 update (with acknowledgement to the late Helen Lester for her contribution to the original 2012 version). London: Royal College of Psychiatrists. Available at: www.rcpsych.ac.uk/workinpsychiatry/qualityimprovement/nationalclinicalaudits/nationalschizophreniaaudit/nasresources.aspx.Google Scholar

Simon, V, van Winkel, R, De Hert, M (2009). Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry, 70, 1041–1050.Google Scholar

Snigdha, S, Thumbi, C, Reynolds, GP, et al. (2008). Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. J Psychopharmacol, 22, 567–571.Google Scholar

Spelman, LM, Walsh, PI, Sharifi, N, et al. (2007). Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabetes Med, 24, 481–485.Google Scholar

Speyer, H, Christian Brix Nørgaard, H, Birk, M, et al. (2016). The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity. World Psychiatry, 15(2), 155–165.Google Scholar

Stahl, SM, Cucchiaro, J, Simonelli, D, et al. (2013). Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry, 74, 507–515.Google Scholar

Stokes, C, Peet, M (2004). Dietary sugar and polyunsaturated fatty acid consumption as predictors of severity of schizophrenia symptoms. Nutr Neurosci, 7, 247–249.Google Scholar

Tagami, K, Kashiwase, Y, Yokoyama, A, et al. (2016). The atypical antipsychotic, olanzapine, potentiates ghrelin-induced receptor signaling: an in vitro study with cells expressing cloned human growth hormone secretagogue receptor. Neuropeptides, 58, 93–101.Google Scholar

Taylor, D, Paton, C, Kapur, S (2012). The Maudsley Prescribing Guidelines in Psychiatry, 11th ed. London: Wiley Blackwell.Google Scholar

Teasdale, SB, Ward, PB, Rosenbaum, S, et al. (2017). Solving a weighty problem: systematic review and meta-analysis of nutrition interventions in sevmental illness. Br J Psychiatry, 210, 110–118.Google Scholar

Tidey, JW, Miller, ME (2015). Smoking cessation and reduction in people with chronic mental illness. BMJ, 351, h4065.Google Scholar

Tiihonen, J, Lönnqvist, J, Wahlbeck, K, et al. (2009). 11-year follow-up of mortality in patients with schizophrenia, a population-based cohort study (FIN11 study). Lancet, 374, 620–627.Google Scholar

Toalson, P, Ahmed, S, Hardy, T, et al. (2004). The metabolic syndrome in patients with severe mental illnesses. Prim Care Companion J Clin Psychiatry, 6, 152–158.Google Scholar

Vancampfort, D, Wampers, M, Mitchell, AJ, et al. (2013). A meta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry, 12, 240–250.Google Scholar

Vandenberghe, F, Gholam-Rezaee, M, Saigí-Morgui, N (2015). Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. J Clin Psychiatry, 76, e1417–e1423.Google Scholar

Wang, H, Peng, D-Q (2011). New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. Lipids Health Dis, 10, 176. https://doi.org/10.1186/1476-511X-10–176.Google Scholar

Weiden, PJ, Mackell, JA, McDonnell, DD (2004). Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res, 66, 51–57.Google Scholar

Weiden, PJ, Newcomer, JW, Loebel, AD, et al. (2008). Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology, 33, 985–994.Google Scholar

Williams, JM, Foulds, J (2007). Successful tobacco dependence treatment in schizophrenia. Am J Psychiatry, 164, 222–227.Google Scholar

World Health Organization (2010). Hidden cities: unmasking and overcoming health inequities in urban settings. Geneva: WHO Press.Google Scholar

Wu, RR, Jin, H, Gao, K, et al. (2012). Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia, a double-blind, randomized, placebo-controlled study. Am J Psychiatry, 169, 813–821.Google Scholar

Yevtushenko, OO, Cooper, SJ, O’Neill, R, et al. (2008). Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry, 192, 424–428.Google Scholar

Zhang, JP, Lencz, T, Zhang, RX, et al. (2016). Pharmacogenetic associations of antipsychotic drug-related weight gain, a systematic review and meta-analysis. Schizophr Bull, 42, 1418–1437.Google Scholar

Zhang, ZJ, Yao, ZJ, Liu, W, et al. (2004). Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry, 184, 58–62.Google Scholar

Zhu, Y, Krause, M, Huhn, M, et al. (2017). Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry, 4(9), 694–705.Google Scholar

Book contents

Part 3 - Specific Therapeutic Areas

Access options

References

References

References

References

References

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive